Table 2.
Response to radiation (RT) and temozolomide (TMZ) of Mayo Primary GBM panel
| Survival Ratio (p-value) | ||||
|---|---|---|---|---|
| GBM# | MS-PCR | TMZ | RT | TMZ/RT |
| GBM5 | M | 5.84 (<0.0001) | 2.53 (0.0003) | 6.35 (<0.0001) |
| GBM6 | U | 1.39 (0.0005) | 1.02 (0.23) | 2.39 (0.04) |
| GBM8 | M | 2.11 (<0.0001) | 1.83 (0.001) | 3.23 (0.07) |
| GBM10 | U | 1.34 (0.10) | 1.61 (0.003) | 1.85 (0.0003) |
| GBM12 | M | 3.53 (<0.0001) | 2.47 (<0.0001) | 5.70 (<0.0001) |
| GBM14 | M | 5.64 (<0.0001) | 1.68 (<0.0001) | 5.70 (0.0003) |
| GBM15 | M | 4.68 (0.0001) | 4.63 (<0.0001) | 4.67 (0.0001) |
| GBM16 | M | 6.85 (0.02) | 1.35 (0.47) | 7.22 (0.10) |
| GBM22 | M | 3.59 (0.0009) | 1.00 (0.29) | 7.57 (0.0009) |
| GBM26 | U | 1.21 (0.003) | 1.58 (0.0001) | 1.58 (0.0001) |
| GBM28 | U | 1.70 (0.003) | 2.06 (0.0001) | 2.50 (<0.0001) |
| GBM34 | U | 4.31 (<0.0001) | 1.84 (0.01) | 4.60 (0.0001) |
| GBM36 | M | 1.82 (0.14) | 1.55 (0.05) | 2.45 (0.02) |
| GBM38 | U | 1.45 (0.0001) | 1.04 (0.21) | 1.36 (0.003) |
| GBM39 | M | 3.87 (<0.0001) | 1.63 (<0.0001) | 6.52 (<0.0001) |
| GBM43 | U | 1.79 (0.003) | 1.71 (0.04) | 2.29 (0.002) |
| GBM44 | U | 1.69 (0.05) | 2.97 (0.008) | 3.23 (<0.0001) |
| GBM46 | M | 1.13 (0.22) | 2.31 (0.0007) | 2.54 (<0.0001) |
| GBM58 | U | 1.11 (0.25) | 1.09 (0.35) | 1.21 (0.14) |
| GBM59 | M | 1.96 (<0.0001) | 1.61 (0.0004) | 5.52 (<0.0001) |
MS-PCR – methylation specific PCR; M – methylated, U – unmethylated Survival ratio is the ratio of median survival for treatment vs. placebo. p-value refers to the comparison of survival for the indicated treatment relative to placebo treatment. Reproduced from (Carlson, 2009). Mice were treated with TMZ at 66 mg/kg/day for 5 days and/or RT at 2 Gy twice per day × 5 days. Dosing was initiated 2 weeks prior to mice anticipated to become moribund for a given tumor line.